questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the National Institute for Health and Care Excellence (NICE)'s current Highly Specialised Technologies Guidance, specifically where it does not recommend a treatment for a rare disease where treatment would have a substantial effect of a medicine on quality and length of life, but is not recommended due to cost-effectiveness estimates being higher than what NICE usually considers an acceptable use of NHS resources for Highly Specialised Technologies.
answerText: The National Institute for Health and Care Excellence (NICE) operates a separate Highly Specialised Technologies (HST) programme to evaluate a very small number of medicines and treatments developed for ultra‑rare, severe and life‑limiting conditions. It ...
heading: Rare Diseases: Medical Treatments